Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06055959 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Study acronym: ziMyG
StatusRecruiting
PhasePhase 2/3
Started2024-10-16
View on ClinicalTrials.gov ↗

Amendment history

2026-07-30
Study Status, Contacts/Locations v29
Study sitesdetails revised at 2 of 9 sites
2026-07-28
Study Status, Contacts/Locations v28
Study sitesdetails revised at 1 of 9 sites
2026-07-02
Study Status, Contacts/Locations v27
Study sitesdetails revised at 1 of 9 sites
2026-05-07
Study Status, Contacts/Locations v26
Study sitesdetails revised at 1 of 9 sites
2026-04-23
Study Status, Contacts/Locations v25
Study sitesdetails revised at 2 of 9 sites
Show 24 earlier versions
2026-04-09
Study Status, Contacts/Locations v24
Study sitesdetails revised at 1 of 9 sites
2026-03-26
Study Status, Contacts/Locations v23
Study sitesdetails revised at 1 of 9 sites
2026-02-26
Study Status, Contacts/Locations v22
Study sitesdetails revised at 1 of 9 sites
2026-02-12
Study Status, Contacts/Locations v21
Study sitesdetails revised at 1 of 9 sites
2026-01-05
Study Status, Contacts/Locations v20
Study sitesdetails revised at 1 of 9 sites
2025-12-18
Study Status, Contacts/Locations v19
Study sitesdetails revised at 1 of 9 sites
2025-03-12
Study Status, Contacts/Locations v18
Study sites8→9
2025-02-07
Study Identification, Study Status v17
Re-verified, no change to tracked fields
2025-01-30
Study Status, Contacts/Locations v16
Study sites7→8
2025-01-16
Study Status, Contacts/Locations v15
Study sites6→7
2024-11-21
Study Status, Contacts/Locations v14
Study sites5→6
2024-10-24
Study Status v13
Start dateestimated 2024-10-15→confirmed 2024-10-16
2024-10-15
Study Status v12
Start date2024-09-16→2024-10-15
2024-08-14
Study Status v11
Primary completion date2026-10-26→2026-11-16
Completion date2026-12-04→2026-12-25
Start date2024-07-15→2024-09-16
2024-06-28
Study Status v10
Start date2024-06-11→2024-07-15
2024-06-20
Study Status, Contacts/Locations v9
Study sites4→5
2024-05-13
Study Status v8
Start date2024-05-07→2024-06-11
2024-05-09
Study Status, Contacts/Locations v7
Study sites3→4
2024-04-30
Study Status v6
Start date2024-04-25→2024-05-07
2024-04-11
Study Status, Contacts/Locations v5
Study sites1→3
2024-04-11
Study Status v4
Start date2024-03-18→2024-04-25
2024-03-06
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start date2024-01-31→2024-03-18
Study sites0→1
2023-12-18
Study Status, Eligibility v2
Start date2024-01→2024-01-31
Eligibility criteria+289 characters
Inclusion Criteria: United States of America (USA) specific inclusion criterion: - Participant must be 12 to <18 years of age at the time of signing the Informed consent/assent according to local regulation Rest of world (ROW) specific inclusion criterion: - Participant must be 2 to <18 years of age at the time of sig [...] g the Informed consent/assent according to local regulation Global inclusion criteria: Participant has a diagnosis of generalized myasthenia gravis [...] le in children from 2 years to <12 years of age at Screening (does not apply to US) Documented vaccination against meningococcal infec [...]
2023-11-21
Study Identification, Study Status v1
Start date2023-09-29→2024-01
2023-09-20
Original filing
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Trial Details
NCT Number NCT06055959
Lead Sponsor UCB Biopharma SRL
Conditions Generalized Myasthenia Gravis
Enrollment 8 participants
Start Date 2024-10-16
Primary Completion 2026-11-16 (estimated)
Study Completion 2026-12-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-31